Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by StockNews.com

StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group upgraded Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 price target for the company in a report on Thursday, July 11th.

Brainstorm Cell Therapeutics Trading Up 6.8 %

BCLI stock opened at $0.36 on Friday. The firm has a 50 day simple moving average of $0.43 and a 200-day simple moving average of $0.43. The company has a market capitalization of $25.16 million, a P/E ratio of -1.12 and a beta of 0.37. Brainstorm Cell Therapeutics has a twelve month low of $0.13 and a twelve month high of $1.90.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. On average, research analysts predict that Brainstorm Cell Therapeutics will post -0.14 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC acquired a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics as of its most recent SEC filing. 14.33% of the stock is owned by hedge funds and other institutional investors.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.